Indian Journal of Critical Care Medicine

Register      Login



Volume / Issue

Online First

Related articles

VOLUME 26 , ISSUE 1 ( January, 2022 ) > List of Articles


Measurement of Interleukin-6 Levels in COVID: Illuminative or Illogical?

Keywords : COVID-19 mortality, Interleukin-6 receptor antagonists, Interleukin-6

Citation Information : Measurement of Interleukin-6 Levels in COVID: Illuminative or Illogical?. Indian J Crit Care Med 2022; 26 (1):9-10.

DOI: 10.5005/jp-journals-10071-24102

License: CC BY-NC 4.0

Published Online: 17-01-2022

Copyright Statement:  Copyright © 2022; The Author(s).


  1. Kishimoto T. IL-6: from its discovery to clinical applications. Int Immunol 2010;22(5):347–352. DOI: 10.1093/intimm/dxq030.
  2. Coomes EA, Haghbayan H. Interleukin-6 in Covid-19: a systematic review and meta-analysis. Rev Med Virol 2020;30(2):e2141. DOI: 10.1002/rmv.2141.
  3. Liu X, Shi S, Xiao J, Wang H, Chen L, Li J, et al. Prediction of the severity of the coronavirus disease and its adverse clinical outcomes. Jpn J Infect Dis 2020;73(6):404–410. DOI: 10.7883/yoken.JJID. 2020.194.
  4. Henry BM, De Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med (CCLM) 2020;58(7):1021–1028. DOI: 10.1515/cclm-2020-0369.
  5. Talwar D, Kumar S, Acharya S, Raisinghani N, Madaan S, Hulkoti V, et al. Interleukin 6 and Its Correlation with COVID-19 in Terms of Outcomes in an Intensive Care Unit of a Rural Hospital: A Cross-sectional Study. Indian J Crit Care Med 2022;26(1):39–42.
  6. Liu X, Wang H, Shi S, Xiao J. Association between IL-6 and severe disease and mortality in COVID-19 disease: a systematic review and meta-analysis. Postgrad Med J 2021; postgradmedj-2021-139939. DOI: 10.1136/postgradmedj-2021-139939.
  7. Nilsonne G, Lekander M, Åkerstedt T, Axelsson J, Ingre M. Diurnal variation of circulating interleukin-6 in humans: a meta-analysis. PLoS One 2016;11(11):e0165799. DOI: 10.1371/journal.pone. 0165799.
  8. Chen X, Zhou J, Chen C, Hou B, Ali A, Li F, et al. Consecutive monitoring of interleukin-6 is needed for COVID-19 patients. Virol Sin 2021;36(5):1093–1096. DOI: 10.1007/s12250-021-00425-4.
  9. Jostock T, Müllberg J, Özbek S, Atreya R, Blinn G, Voltz N, et al. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur J Biochem 2001;268(1):160–167. DOI: 10.1046/j.1432-1327.2001.01867.x.
  10. Dorgham K, Quentric P, Goekkaya M, Marot S, Parizot C, Sauce D, et al. Distinct cytokine profiles associated with COVID-19 severity and mortality. J Allergy Clin Immunol 2021;147(6):2098–2107. DOI: 10.1016/j.jaci.2021.03.047.
  11. The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-Hari M, Vale CL, Godolphin PJ, Fisher D, Higgins JPT, Spiga F, et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis. Journal of the American Medical Association 2021;326(6):499–518. DOI: 10.1001/jama.2021.11330.
  12. Galvan-Roman JM, Rodriguez-Garcia SC, Roy-Vallejo E, et al. IL-6 serum levels predict severity and response to tocilizumab in COVID-19: an observational study. J Allergy Clin Immunol 2020;147(1):72–80. DOI: 10.1016/j.jaci.2020.09.018.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.